I-SPY 2 Trial Consortium 2022, ' Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients ', The Lancet Oncology, vol. 23, no. 1, pp. 149-160 . https://doi.org/10.1016/S1470-2045(21)00589-1 The Lancet. Oncology, vol 23, iss 1 The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group
Nature Sammut, S-J, Crispin-Ortuzar, M, Chin, S-F, Provenzano, E, Bardwell, H A, Ma, W, Cope, W, Dariush, A, Dawson, S-J, E. Abraham, J, Dunn, J, Hiller, L, Thomas, J, Cameron, D A, Bartlett, J, Hayward, L, Pharoah, P D, Markowetz, F, Rueda, O M, Earl, H M & Caldas, C 2021, ' Multi-omic machine learning predictor of breast cancer therapy response ', Nature, vol. 601, pp. 623–629 . https://doi.org/10.1038/s41586-021-04278-5
Breast Cancer Research and Treatment Palmieri, C, Stein, R C, Liu, X, Hudson, E, Nicholas, H, Sasano, H, Guestini, F, Holcombe, C, Barrett, S, Kenny, L, Reed, S, Lim, A, Hayward, L, Howell, S, Coombes, R C & IrisTrial Participants 2017, ' IRIS study : a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients ', Breast Cancer Research and Treatment, pp. 1-11 . https://doi.org/10.1007/s10549-017-4328-z
Earl, H M, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Harnett, A N, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J E, Caldas, C, Hall, P S, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D A & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191, pp. 2599-2612 . https://doi.org/10.1016/S0140-6736(19)30650-6 Lancet (London, England)